COMPANY PROFILE

Exeliom Biosciences

Explore full profile

Developing single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics

Dijon, FranceFounded 2016Biotech & Life Sciences

Valuation $25–50M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Exeliom Biosciences

Exeliom Biosciences is a pioneering startup focused on developing innovative therapies that leverage the microbiome—the community of microorganisms living in our bodies—to treat diseases. The company primarily targets inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, which cause chronic inflammation of the digestive tract. Unlike traditional treatments that suppress the immune system, Exeliom's drug candidates aim to modulate, or adjust, the immune response without suppressing it. This makes their therapies more suitable for long-term use, especially for patients with mild to moderate symptoms.

Read full description

Exeliom Biosciences operates in the biopharmaceutical market, a sector dedicated to developing drugs based on biological sources. Their clients include healthcare providers, hospitals, and patients suffering from chronic inflammatory conditions. The company collaborates with scientific experts, including Professor Harry Sokol from Saint Antoine Hospital in Paris, to ensure their therapies are grounded in cutting-edge research.

The business model of Exeliom Biosciences revolves around research and development (R&D) of new drug candidates. They invest heavily in scientific research to discover and develop these therapies. Once a drug candidate shows promise, it undergoes rigorous clinical trials to ensure its safety and efficacy. If successful, the company can then license the drug to pharmaceutical companies or sell it directly to healthcare providers. This is how Exeliom Biosciences generates revenue—through the commercialization of their innovative therapies.

In summary, Exeliom Biosciences is at the forefront of a new generation of medicine, focusing on the microbiome to create non-suppressive, immune-modulating therapies for chronic inflammatory diseases. Their patient-centric approach and commitment to scientific excellence position them as a promising player in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Dijon, France
Employees: 9
Open positions: None listed
Dealroom signal: 58.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, EIC, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Horizon Europe, observatoire industrial tech, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2025	$3.1M	$44M	UI Investissement · Forepont Capital Partners · Crescent Ventures · BIOCODEX	↗
SERIES A✓Equity / VC	Jul 2023	$8.8M	$35M	Auriga Partners · BIOCODEX · Crescent Enterprises · UI Investissement	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Exeliom Biosciences website traffic

Latest recorded traffic for Exeliom Biosciences is 1.6K monthly website visits, up 105.1% over the last three months. Exeliom Biosciences's team grew 0% over the past year.

Latest monthly visits1.6K 3-month web change+105.1% 1-year team growth0%

Monthly website visitsApr 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational	22	$29M	$88M
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
SMSPARTHA MEDICALDevelops coatings based on natural biopolymers with antimicrobial, antiviral, and anti-inflammatory properties	Strasbourg, France	Operational
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational